Recent cardiovascular outcome trial results have led to the expansion of indications for SGLT2 inhibitors for patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). These medications have also been proven to prevent heart failure readmission in high risk patients. Review this course to learn about SGLT2 inhibitors - how they work and their updated indications. 

Learner Objectives
Upon completion of this activity, you should be able to:
     - Evaluate the relevant clinical trials that impact the emerging indications of SGLT2 inhibitors

Target Audience 
Global CV team clinicians including physicians, nurse practitioners, physician assistants and pharmacist who recommend or prescribe SGLT2 inhibitors for patients with ASCVD and/or heart failure.

Faculty:
Hani Mohamed Sabbour, MD, FACC
Cleveland Clinic Abu Dhabi

Acknowledgments
Educational grant support provided by: Boehringer Ingelheim Pharmaceuticals Inc.

Disclaimer: This activity does not offer credit.